Moderna under pressure despite RSV vaccine approval into wider age group

3 weeks ago 2

• Healthcare

hapabapa/iStock Editorial via Getty Images

• Moderna (NASDAQ:MRNA) shares are down ~2% in early Friday trading despite the U.S. FDA approving the company's RSV shot RSV, mRESVIA (mRNA-1345), in an expanded population.
• Although the approval is a positive for the company, it could face an uphill climb

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Moderna under pressure despite RSV vaccine approval into wider age group